Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab)

Trial Profile

Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2016

At a glance

  • Drugs Pembrolizumab (Primary) ; Dactolisib; Ipatasertib; Pictrelisib
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2016 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 27 Nov 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Nov 2015, according to ClinicalTrials.gov record.
    • 27 Nov 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top